CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients
Identifieur interne : 002C69 ( Main/Exploration ); précédent : 002C68; suivant : 002C70CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients
Auteurs : Xiaorong Lin [République populaire de Chine] ; Nancy H. Gudgeon [Royaume-Uni] ; Edwin P. Hui [République populaire de Chine] ; Hui Jia [Royaume-Uni] ; Xue Qun [République populaire de Chine] ; Graham S. Taylor [Royaume-Uni] ; Martin C. N. M. Barnardo [Royaume-Uni] ; C. Kit Lin [République populaire de Chine] ; Alan B. Rickinson [Royaume-Uni] ; Anthony T. C. Chan [République populaire de Chine]Source :
- Cancer Immunology, Immunotherapy [ 0340-7004 ] ; 2008-07-01.
English descriptors
- KwdEn :
Abstract
Abstract: Nasopharyngeal carcinoma (NPC), an Epstein–Barr virus (EBV)-associated tumour common in Southern Chinese populations, is a potentially important target for T cell-based immunotherapy. The tumour cells are HLA class I- and II-positive and express a limited subset of EBV latent proteins, namely the nuclear antigen EBNA1 and the latent membrane proteins LMP2 and (in some cases) LMP1. To ask whether the tumour develops in the presence of a potentially protective host response or in its absence, we set out to determine the prevailing levels of CD4+ and CD8+ T cell memory to these proteins in NPC patients at tumour diagnosis. We first screened healthy Chinese donors against Chinese strain EBNA1, LMP1 and LMP2 sequences in Elispot assays of interferon-γ release and identified the immunodominant CD4+ and CD8+ epitope peptides presented by common Chinese HLA alleles. Then, comparing 60 patients with >70 healthy controls on peptide epitope mini-panels, we found that T cell memory to CD4 epitopes in all three proteins was unimpaired in the blood of patients at diagnosis. In most cases NPC patients also showed detectable responses to CD8 epitopes relevant to their HLA type, the one consistent exception being the absence in patients of a B*4001-restricted response to LMP2. We infer that NPC arises in patients whose prevailing levels of T cell memory to tumour-associated EBV proteins is largely intact; the therapeutic goal must therefore be to re-direct the existing memory repertoire more effectively against antigen-expressing tumour cells.
Url:
DOI: 10.1007/s00262-007-0427-8
Affiliations:
- Royaume-Uni, République populaire de Chine
- Angleterre, Midlands de l'Ouest, Oxfordshire
- Birmingham, Oxford, Sha Tin
- Université chinoise de Hong Kong, Université d'Oxford, Université de Birmingham
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A21
- to stream Istex, to step Curation: 000A21
- to stream Istex, to step Checkpoint: 000922
- to stream Main, to step Merge: 002C95
- to stream Main, to step Curation: 002C69
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients</title><author><name sortKey="Lin, Xiaorong" sort="Lin, Xiaorong" uniqKey="Lin X" first="Xiaorong" last="Lin">Xiaorong Lin</name></author><author><name sortKey="Gudgeon, Nancy H" sort="Gudgeon, Nancy H" uniqKey="Gudgeon N" first="Nancy H." last="Gudgeon">Nancy H. Gudgeon</name></author><author><name sortKey="Hui, Edwin P" sort="Hui, Edwin P" uniqKey="Hui E" first="Edwin P." last="Hui">Edwin P. Hui</name></author><author><name sortKey="Jia, Hui" sort="Jia, Hui" uniqKey="Jia H" first="Hui" last="Jia">Hui Jia</name></author><author><name sortKey="Qun, Xue" sort="Qun, Xue" uniqKey="Qun X" first="Xue" last="Qun">Xue Qun</name></author><author><name sortKey="Taylor, Graham S" sort="Taylor, Graham S" uniqKey="Taylor G" first="Graham S." last="Taylor">Graham S. Taylor</name></author><author><name sortKey="Barnardo, Martin C N M" sort="Barnardo, Martin C N M" uniqKey="Barnardo M" first="Martin C. N. M." last="Barnardo">Martin C. N. M. Barnardo</name></author><author><name sortKey="Lin, C Kit" sort="Lin, C Kit" uniqKey="Lin C" first="C. Kit" last="Lin">C. Kit Lin</name></author><author><name sortKey="Rickinson, Alan B" sort="Rickinson, Alan B" uniqKey="Rickinson A" first="Alan B." last="Rickinson">Alan B. Rickinson</name></author><author><name sortKey="Chan, Anthony T C" sort="Chan, Anthony T C" uniqKey="Chan A" first="Anthony T. C." last="Chan">Anthony T. C. Chan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D556528C5F0C0367B8DCD93316977E46F7FDAA00</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1007/s00262-007-0427-8</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-5RQ9KQDS-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A21</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A21</idno><idno type="wicri:Area/Istex/Curation">000A21</idno><idno type="wicri:Area/Istex/Checkpoint">000922</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000922</idno><idno type="wicri:doubleKey">0340-7004:2007:Lin X:cd:and:cd</idno><idno type="wicri:Area/Main/Merge">002C95</idno><idno type="wicri:Area/Main/Curation">002C69</idno><idno type="wicri:Area/Main/Exploration">002C69</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients</title><author><name sortKey="Lin, Xiaorong" sort="Lin, Xiaorong" uniqKey="Lin X" first="Xiaorong" last="Lin">Xiaorong Lin</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Sir Y. K. Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Gudgeon, Nancy H" sort="Gudgeon, Nancy H" uniqKey="Gudgeon N" first="Nancy H." last="Gudgeon">Nancy H. Gudgeon</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, B15 2TT, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName><orgName type="university">Université de Birmingham</orgName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Hui, Edwin P" sort="Hui, Edwin P" uniqKey="Hui E" first="Edwin P." last="Hui">Edwin P. Hui</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Sir Y. K. Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Jia, Hui" sort="Jia, Hui" uniqKey="Jia H" first="Hui" last="Jia">Hui Jia</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, B15 2TT, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName><orgName type="university">Université de Birmingham</orgName></affiliation></author><author><name sortKey="Qun, Xue" sort="Qun, Xue" uniqKey="Qun X" first="Xue" last="Qun">Xue Qun</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Sir Y. K. Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Taylor, Graham S" sort="Taylor, Graham S" uniqKey="Taylor G" first="Graham S." last="Taylor">Graham S. Taylor</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, B15 2TT, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName><orgName type="university">Université de Birmingham</orgName></affiliation></author><author><name sortKey="Barnardo, Martin C N M" sort="Barnardo, Martin C N M" uniqKey="Barnardo M" first="Martin C. N. M." last="Barnardo">Martin C. N. M. Barnardo</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Transplant Immunology, Oxford Transplant Centre, University of Oxford, Churchill Hospital, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Lin, C Kit" sort="Lin, C Kit" uniqKey="Lin C" first="C. Kit" last="Lin">C. Kit Lin</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hong Kong Red Cross Blood Transfusion Service, Kowloon, Hong Kong</wicri:regionArea><wicri:noRegion>Hong Kong</wicri:noRegion></affiliation></author><author><name sortKey="Rickinson, Alan B" sort="Rickinson, Alan B" uniqKey="Rickinson A" first="Alan B." last="Rickinson">Alan B. Rickinson</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, B15 2TT, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName><orgName type="university">Université de Birmingham</orgName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Chan, Anthony T C" sort="Chan, Anthony T C" uniqKey="Chan A" first="Anthony T. C." last="Chan">Anthony T. C. Chan</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Sir Y. K. Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Cancer Immunology, Immunotherapy</title><title level="j" type="abbrev">Cancer Immunol Immunother</title><idno type="ISSN">0340-7004</idno><idno type="eISSN">1432-0851</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2008-07-01">2008-07-01</date><biblScope unit="volume">57</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="963">963</biblScope><biblScope unit="page" to="975">975</biblScope></imprint><idno type="ISSN">0340-7004</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-7004</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CD4</term><term>CD8</term><term>Epstein–Barr virus</term><term>Nasopharyngeal carcinoma</term><term>T cell</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Nasopharyngeal carcinoma (NPC), an Epstein–Barr virus (EBV)-associated tumour common in Southern Chinese populations, is a potentially important target for T cell-based immunotherapy. The tumour cells are HLA class I- and II-positive and express a limited subset of EBV latent proteins, namely the nuclear antigen EBNA1 and the latent membrane proteins LMP2 and (in some cases) LMP1. To ask whether the tumour develops in the presence of a potentially protective host response or in its absence, we set out to determine the prevailing levels of CD4+ and CD8+ T cell memory to these proteins in NPC patients at tumour diagnosis. We first screened healthy Chinese donors against Chinese strain EBNA1, LMP1 and LMP2 sequences in Elispot assays of interferon-γ release and identified the immunodominant CD4+ and CD8+ epitope peptides presented by common Chinese HLA alleles. Then, comparing 60 patients with >70 healthy controls on peptide epitope mini-panels, we found that T cell memory to CD4 epitopes in all three proteins was unimpaired in the blood of patients at diagnosis. In most cases NPC patients also showed detectable responses to CD8 epitopes relevant to their HLA type, the one consistent exception being the absence in patients of a B*4001-restricted response to LMP2. We infer that NPC arises in patients whose prevailing levels of T cell memory to tumour-associated EBV proteins is largely intact; the therapeutic goal must therefore be to re-direct the existing memory repertoire more effectively against antigen-expressing tumour cells.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>République populaire de Chine</li></country><region><li>Angleterre</li><li>Midlands de l'Ouest</li><li>Oxfordshire</li></region><settlement><li>Birmingham</li><li>Oxford</li><li>Sha Tin</li></settlement><orgName><li>Université chinoise de Hong Kong</li><li>Université d'Oxford</li><li>Université de Birmingham</li></orgName></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Lin, Xiaorong" sort="Lin, Xiaorong" uniqKey="Lin X" first="Xiaorong" last="Lin">Xiaorong Lin</name></noRegion><name sortKey="Chan, Anthony T C" sort="Chan, Anthony T C" uniqKey="Chan A" first="Anthony T. C." last="Chan">Anthony T. C. Chan</name><name sortKey="Chan, Anthony T C" sort="Chan, Anthony T C" uniqKey="Chan A" first="Anthony T. C." last="Chan">Anthony T. C. Chan</name><name sortKey="Hui, Edwin P" sort="Hui, Edwin P" uniqKey="Hui E" first="Edwin P." last="Hui">Edwin P. Hui</name><name sortKey="Hui, Edwin P" sort="Hui, Edwin P" uniqKey="Hui E" first="Edwin P." last="Hui">Edwin P. Hui</name><name sortKey="Lin, C Kit" sort="Lin, C Kit" uniqKey="Lin C" first="C. Kit" last="Lin">C. Kit Lin</name><name sortKey="Qun, Xue" sort="Qun, Xue" uniqKey="Qun X" first="Xue" last="Qun">Xue Qun</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Gudgeon, Nancy H" sort="Gudgeon, Nancy H" uniqKey="Gudgeon N" first="Nancy H." last="Gudgeon">Nancy H. Gudgeon</name></region><name sortKey="Barnardo, Martin C N M" sort="Barnardo, Martin C N M" uniqKey="Barnardo M" first="Martin C. N. M." last="Barnardo">Martin C. N. M. Barnardo</name><name sortKey="Gudgeon, Nancy H" sort="Gudgeon, Nancy H" uniqKey="Gudgeon N" first="Nancy H." last="Gudgeon">Nancy H. Gudgeon</name><name sortKey="Jia, Hui" sort="Jia, Hui" uniqKey="Jia H" first="Hui" last="Jia">Hui Jia</name><name sortKey="Rickinson, Alan B" sort="Rickinson, Alan B" uniqKey="Rickinson A" first="Alan B." last="Rickinson">Alan B. Rickinson</name><name sortKey="Rickinson, Alan B" sort="Rickinson, Alan B" uniqKey="Rickinson A" first="Alan B." last="Rickinson">Alan B. Rickinson</name><name sortKey="Taylor, Graham S" sort="Taylor, Graham S" uniqKey="Taylor G" first="Graham S." last="Taylor">Graham S. Taylor</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D556528C5F0C0367B8DCD93316977E46F7FDAA00
|texte= CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients
}}
| This area was generated with Dilib version V0.6.33. |  |